Amarantus Bioscience Holdings Inc (AMBS)

[jrock777]

I have had a few dozen calls from people inquiring my thoughts on the split. I will say that I am super excited about the direction of AMBS. With International Infusion being one of the major shareholders of the stock, I am happy to see the company executing on its current plan to be listed on the NSDQ. We have clinicals starting for our phase 2b this quarter and we are with finalizing the acquisition of ESS. This reverse is going to allow the pathway for major institutions to invest and we have already had disclaimers in the past from JP Morgan and Fidelity. The float is going to be much more lean which is going to help control volatility. As the maker institutions buying substantial parts of the float we will see more consistency in our price points. Another thing people constantly ask is about the dilution. This is a bio tech and is going to have dilution which does create value by giving the necessary resources to make acquisitions and advance the programs. You can count on the two billion shares to one day be used. If you double the share count which also doubles the market cap we are still way below the value of 180mm which zacks evaluated us at. And remember that valuation is without ESS and without consideration of trials starting for both ESS and eltropozine. People also have asked about cash flow concerns. Remember this quarterly report does not show the $5mm that was just raised and worse case we have $12mm left on the equity line. There have been a lot of strides over the past few years and we truly are a diversified bio company with some iconic names in the space. Simply put, when the institutions buy it is going to be a lot more difficult to get those shares from them.